Povorcitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: June 2, 2026

The clinical evidence base for Povorcitinib comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including . Most recent publication: Development and validation of a bioanalytical method to quantify povorcitinib in human skin with clinical application., Bioanalysis, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Development and validation of a bioanalytical method to quantify povorcitinib in human skin with clinical application.
Xun Z, Zhang L, Wen H, et al. · Bioanalysis · 2026
PubMed: PMID 41504465 · NCT06505265

Publications by year

2026–2026: 1 publications.

2026

Publications by journal

Bioanalysis1 paper

All Povorcitinib publications (1)

2026 (1 paper)

Development and validation of a bioanalytical method to quantify povorcitinib in human skin with clinical application.
Xun Z, Zhang L, Wen H, et al. · Bioanalysis · 2026 · Derived
PubMed: PMID 41504465 · NCT06505265

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 02 Jun 2026 17:13:31 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).